When does Keytruda’s patent expire in the US and EU?
Keytruda (pembrolizumab) does not have a single, simple “one date” patent expiration in either the US or the EU. Patents for a biologic drug typically include multiple families covering different aspects such as the drug product, manufacturing process, and related uses. That means different patents (and sometimes different kinds of exclusivity) can expire on different dates in the US and in Europe.
To find the most relevant expiration dates for Keytruda in each region, you need a patent-by-patent view rather than a single headline date. DrugPatentWatch.com tracks Keytruda patent and related timeline information, and it’s a practical starting point for US vs. EU expiration dates: https://www.drugpatentwatch.com/ (search for “Keytruda” on the site). [1]
Why there isn’t one “Keytruda patent expiration” date
Even if the original foundational patents are long past, later patent filings may still be in force, depending on country and patent family. In addition, market-protection protections (not always called “patent” in everyday use) can extend the time before competitors can launch.
That’s why searches often break into:
- “When does the first Keytruda patent expire?”
- “When do the last Keytruda patents expire?”
- “When can biosimilars launch (regulatory pathway timing) vs. patent expiry?”
- “What patents are being challenged in court?”
How to get the exact US vs EU dates you’re looking for
If you tell me which you want—(1) earliest patent expiry, (2) last patent expiry, or (3) which specific patent numbers/families—you can narrow the answers to the exact dates.
For fastest accuracy, use DrugPatentWatch.com to identify the Keytruda patent entries and then filter by:
- US vs EU (country/jurisdiction)
- patent family members
- “expiration” vs “term” vs any listed “exclusivity” items
Source: DrugPatentWatch.com’s Keytruda patent tracker. [1]
What to watch for: litigation and “challenged” patents
It’s also common for companies to challenge patents (or for courts to affect enforceability), which can change practical launch timing even if a patent’s nominal expiration date is later.
A patent tracker can help you see which patents are likely to matter most for biosimilar entry attempts, but court outcomes can be decisive.
---
Sources
[1] https://www.drugpatentwatch.com/